evitria Partners with Sapio Sciences to streamline antibody workflow management and reporting
Leading antibody expression service provider implements Sapio’s ELN and Report Builder for advanced sample tracking and data management
Orbit Discovery and Evergreen Theragnostics expand research collaboration to advance targeted therapeutics development
Oxford, UK, and Springfield, NJ, USA, 3rd December 2024: Orbit Discovery, a leading provider of peptide discovery services, and Evergreen Theragnostics, a radiopharmaceutical company at the forefront of precision medicine, today announced an extension to their research
Case Study: Thames Valley and Surrey Secure Data Environment
The Thames Valley and Surrey Secure Data Environment (SDE) case study highlights the collaboration between NHS and System C to enhance data security and accessibility. The SDE integrates data from multiple sources, providing a secure platform for health and care professionals to access and analyse patient information.
Navigating the EU’s General Product Safety Regulations (GPSR)
Webinar on Tuesday, 10 December 2024, from 1:00 PM to 2:30 PM UK Time to help businesses prepare for the General Product Safety Regulation (GPSR) deadline on 13 December 2024.
Drive business success with Best Employers Eastern Region 2025
Best Employers has been changing the face of employee engagement since 2012, by helping organisations get a deeper understanding of their employees through a detailed engagement survey. Personalised results and tailored action plans then help them evolve their workplaces for the better.
Targeting IL-23, Medicilon assists the development of a variety of new drugs for Psoriasis
With people’s in-depth understanding of the inflammatory pathways of psoriasis, biologics continue to develop. From tumor necrosis factor alpha (TNF-α), to IL-17 inhibitors, and then to IL-23 inhibitors, biologics have brought new light to the treatment of psoriasis again. In recent years, the exploration of IL-23 by new drug developers has never stopped. Medicilon Assists IL-23 Monoclonal…
Babraham Research Campus’ £3.15bn life science ecosystem soars
New report reveals how groundbreaking research at the Campus is delivering major gains for UK economic growth and job creation.
Medicilon neural system disease models help our clients advance novel drug development
Medicilon Pharmacodynamics Department can deliver multiple nervous system models based on anti-depressants, anti-Alzheimer's drugs, sedative-hypnotic and anti-anxiety drugs, analgesics, anti-convulsant, anti-Parkinson's drugs, and anti-schizophrenia drugs.
impulse 2025 - the entrepreneurship programme for innovators is now open for applications
impulse is an action-learning programme designed to catalyse the development of high-potential innovation into commercial propositions, guided by experienced entrepreneurs and mentors from the Cambridge innovation cluster. The 3-month hybrid programme – which runs from 29 April to 11 July 2025 – is offered online and in-person via the Maxwell Centre, the University of Cambridge’s hub for…
Tristan backs £300m+ life sciences platform
Tristan Capital Partners’ debt fund has refinanced a £310m prime life science portfolio located across Cambridge and Oxford, Green Street News can reveal.
Centauri Therapeutics awarded £1M grant under new PACE programme to advance immunotherapy platform in anti-infectives
Funding to support further development of lead programme for a novel therapeutic targeting Gram-negative bacteria including Multi-Drug-Resistant strains Optimisation will also support application of the Alphamer® platform across other therapeutic indicat
Metrion Biosciences appoints Lee Patterson as CEO
Significant CRO C-suite experience expected to drive growth and commercial expansion into global marketsCambridge, UK, 25 November 2024: Metrion Biosciences, the specialist preclinical contract research organisation (CRO) and a leader in ion channe
Guardtech Group hoping to end golden year with more success at SME National Business Awards
Suffolk contamination control experts looking to add Best Enterprising Business prize to epic 2024 awards haul at glitzy Wembley Stadium showpiece on 6 December
Medicilon delivers fast turnaround time to meet your FDA submission deadline for SEND Format Conversion
Medicilon's preclinical pharmacology and toxicology research team is equipped with a professional send format conversion team and has established a send data conversion platform that is fully developed in terms of software, technology, specification and quality, to realize accurate data conversion and provide a good environment for electronic data submission.
Human immune system is ‘ready to go’ long before birth
By creating the first spatial atlas of the developing human thymus, a vital organ that trains immune cells to protect against infections and cancer, scientists have discovered that the foundation for lifelong immunity is established earlier than previously thought.
Early skeleton map reveals how bones form in humans
The first ‘blueprint’ of human skeletal development reveals how the skeleton forms, shedding light on the process of arthritis, and highlighting cells involved in conditions that affect skull and bone growth.
Mapping 1.6 million gut cells to find new ways to treat disease
By combining 25 datasets, researchers have created the largest cohesive cell atlas of the human gut and uncovered a new way that stomach cells may play a role in Inflammatory Bowel Disease.
Shining a light on the life sciences
The OBN Awards struck an optimistic tone as the best of the UK’s life sciences industry was celebrated
Glox Therapeutics awarded £1M PACE grant to accelerate development of precision antibiotics against antimicrobial-resistant pathogens
Novel therapeutics to address unmet clinical need for pneumonias caused by drug-resistant Escherichia coli and Klebsiella pneumoniae PACE provides funding and support for innovative, high value, high risk, early phase drug discovery and diagnostic projects
COPD management: a critical look at gaps in pharmaceutical innovation
Chronic Obstructive Pulmonary Disease (COPD) presents a major global health challenge, marked by chronic respiratory decline and frequent exacerbations. Despite advances in treatment, comprehensive management strategies remain limited, revealing significant gaps in patient care.
CrestOptics and Tomocube partner to advance 3D imaging with new multimodal imaging platform
First commercially available spinning-disk confocal holotomographic instrument, enabling advanced 3D imaging with fluorescence-based detection New system showcased at SPAOM24 (20th-22
Tagomics announces a multiomic profiling co-marketing agreement with Agilent
Exclusive program will provide customers with a single, unified workflow for comprehensive genomic profiling and genome-wide epigenetic analysis
Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line
Strategic agreement will accelerate the manufacturing of fully human multispecific therapies for chronic retinal diseases with high unmet need using Asimov’s CHO Edge System
Steritas announces collaboration with argenx to advance evidence for novel steroid-sparing therapeutics
First-in-class steroid-toxicity outcome assessments licensed by argenx to support development of novel steroid-sparing therapeutics for autoimmune diseases
